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OBJECTIVES: To compare cost-effectiveness of rosuvastatin (RSV) versus
ezetimibe/simvastatin (E/S) in achieving LDL-C goals (NCEP-ATP III 2001 and 2004
guidelines), in daily outpatient practice in Mexico.METHODS: Retrospective study.
From January 2004 to December 2010, outpatient medical records in 15 Mexican
hospitals/clinics were reviewed to identify patients with dyslipidemia and their
corresponding serum lipidmeasurements documented before receiving drug ther-
apy with either RSV (5mg, 10mg, or 20mg once daily) or E/S (5/5mg, 10/10mg, 10/
20mg or 10/40mg once daily); and lipid levels recorded at least after 8 weeks of
treatment. The efficacywas assessed by a) the proportion of patients who achieved
the LDL-C goal, and b) the percent reduction in LDL-C after 8 weeks of treatment. A
cost-effectiveness analysis was performed from an institutional perspective, using
the exchange rate of August 2011 of 12.2424 pesos/USD. RESULTS: Using ATP III
2001 criteria, percentage of patients who reached LDL-C goals was RSV: 81.3% and
E/S 77.1% (p  0.2972). Using ATP III 2004 criteria were: RSV, 61.3% vs. E/S, 58.5%
(p0.2548). The average treatment cost was statistically significant higher for E/S
patients (239.49 USD) versus 192.74 USD for RSV patients (p0.0033). The cost of 1%
reduction in LDL-Cwas RSV: 4.69 USD and E/S: 7.13 USD. Cost per patient treated to
ATP-III goal 2001 criteria was: RSV, 219.5 USD versus E/S, 306.0 USD and treated to
ATP-III goal 2004 criteria was: RSV, 282.2 versus E/S, 459.1 USD. The overall inci-
dence rate of adverse events was E/S: 19.5% versus RSV: 15.3%. The percentage of
patients reporting moderate or severe adverse events was E/S: 6.8% and RSV: 4.7%.
CONCLUSIONS: According to this exploratory, non-controlled retrospective study,
in daily clinical practice in Mexican dyslipidemic patients, treatment with RSV has
similar efficacy and safety, but it is more cost-effectiveness than E/S in reaching
cholesterol goals.
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OBJECTIVES: To compare costs and effectiveness of dabigatran etexilate (DAB)
versus warfarin (WAR) in patients with Non-Valvular Atrial Fibrillation (NVAF)
from a private and public health care system perspective in Brazil. METHODS: A
Markov model was built to compare DAB versus WAR to derive the incremental
cost effectiveness ratio (ICER) of DAB, based on the international literature and a
modified Delphi panel with Brazilian experts (local clinical practice pattern on the
management of NVAF patients). The model estimated the number of ischaemic
and haemorrhagic strokes, systemic embolisms, intracranial hemorrhages, tran-
sient ischaemic attacks, extracranial hemorrhages, minor bleeds and acute myo-
cardial infarctions associated with the respective treatments. To each clinical
event costs, disabilities and/or reduction in quality of life, and risk of death were
assigned. Only direct medical costs were considered and a discount rate of 5% was
assumed, according to BrazilianHTA guidelines. A probabilistic sensitivity analysis
was designed to assess uncertainty. RESULTS: Under both, the private and public
perspective, DAB was associated with additional 0.30 life years gained (LY), addi-
tional 0.35 QALYs and demonstrated a lower incidence of intracranial events ver-
sus WAR, resulting in lower event costs and follow-up costs. The ICER for DAB
versus WAR was R$ 39,740/LY and R$ 34,867/QALY from the public and R$
25,252.48/LY and R$ 22,160.20/QALY from the private perspective. Sensitivity anal-
yses confirmed the cost-effectiveness of DAB. CONCLUSIONS: Findings suggest
that DAB can be cost-effective for stroke prevention when used instead of WAR in
NVAF patients in Brazil, given that the ICERS were below the threshold of other
technologies reimbursed.
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OBJECTIVES: To assess the cost-effectiveness of the novel fixed-dose anticogulant,
rivaroxaban, in comparisson to the current dose-volatile standard of care, warfa-
rin, for the prevention of stroke in high-risk atrial fibrillation patients.METHODS:
AMarkovmodel was constructed tomodel the costs and health outcomes of treat-
ments, potential adverse events, and resulting health states over 35 years. Analy-
ses were based on a hypothetical cohort of 65 year-old patients with chronic atrial
fibrillation and high risk of stroke. The main outcome measure was cost per qual-
ity-adjusted-life-years (QALYs) gained over the lifetime andwas assessed from the
UK’s National Health Service (NHS) perspective. Costs and utility data were drawn
from previously published and publically available data, while event probabilities
were adopted from both the literature and limited data from rivoroxaban’s phase
III trial. RESULTS: Stroke prophylaxis with rivaroxaban offers lifetime health im-
provements over warfarin treatment, yet at substantial cost. From the NHS’ per-
spective, rivaroxaban’s baseline cost of £38,121 per QALY exceeds the typical will-
ingness to pay threshold. Nonetheless, the results were sensitive to adjustments of
several key variables,most notably the price of rivaroxaban, utility of warfarin, risk
of bleeding-related eventswithwarfarin, anddiscount rate for outcomes, justifying
further consideration by NICE and the NHS. CONCLUSIONS: Novel anticoagulants
such as rivaroxaban are one of many strategies being considered to replace stan-
dard warfarin therapy andmitigate its compounding weaknesses of frequent dose
regulation and bleeding risk. Our results, though far from offering backbone for the
substitution of rivaroxaban for warfarin treatment across the NHS, justify atten-
tion to this and other fixed-dose therapies as a potential alternative to warfarin-
based stroke prevention strategies. In addition tomore detailed subgroup analysis,
further research ought to consider evaluating patient, caregiver, and indirect costs,
long-term impacts on health-system demand, and comparing novel anticoagula-
tion therapies against each other.
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OBJECTIVES: To estimate the cost-effectiveness of dronedarone in Turkey com-
pared to standard of care (SOC), amiodarone and sotalol as the cost per life-year
gained (LYG). METHODS: Cost-effectiveness of dronedarone compared to SOC,
amiodarone and sotalol was estimated in a health economic microsimulation
model with transition probabilities based on ATHENA trial and relative risks of
events for amiodarone and sotalol are taken from mixed treatment comparison
(MTC) based on a systematic review of the clinical trials of AF. There were 7 health
states; on anti-arrhythmic drug (AAD), off AAD, stroke, post-stroke, chronic heart
failure, post chronic heart failure, acute coronary syndrome, symptomatic AF and
death. Each simulation included 1,000,000 patients; in all simulations patients
were followed for life or end of simulation (max 28 years). Risk of having an adverse
event (AE) for patients on dronedarone compared to SOC was from ATHENA trial
and compared to amiodarone from theDIONYSOS trial. Costswere valued from the
Social Security Institution perspective using official price lists and App2/D dis-
counts. A Delphi survey was conducted with 8 specialists to estimate treatment
and hospitalization costs. RESULTS: Non-permanent AF patients taking droneda-
rone on top of SOC lived on average 0.14 years longer compared with SOC alone.
The incremental cost-effectiveness ratio (ICER) was estimated as 11,400TL/LYG.
When comparing dronedarone with amiodarone and sotalol, patients on droneda-
rone lived 1.17 years and 2.28 years longer respectively. The ICERs for dronedarone
compared to amiodarone and sotalol were estimated as 4,300TL/LYG and 3,100TL/
LYG, respectively. CONCLUSIONS: It is difficult for the results of the analysis to be
interpreted because there is no official cost-effectiveness threshold in Turkey.
From the WHO perspective, however, results showed that dronaderone is a highly
cost-effective treatment with all ICER values compared to SOC, amiodarone and
sotalol below 3 X GDP per capita; 70,857TL (3 X 23,619TL).
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OBJECTIVES: As far as combination of aspirin and clopidogrel was recently recom-
mended by Russian National Society of Cardiology as well as AHA “when oral
anticoagulation with warfarin is considered unsuitable”, the urgent need to com-
pare its cost-effeciveness with novel oral anticoagulant dabigatran is appear.
METHODS: Present study was based on Markov model with 10 years time horizon
simulated the cohort of 10 000 AF patients at moderate-to-high stroke risk while
tracking clinical events and resulting functional disability. Direct expenses associ-
ated with complications and resulting long-term follow-up costs were calculated
using general tariff agreement of Russian obligatory insurance system and official
national statistics. RE-LY, ActiveW trials and publishedmetaanalises were used as
main clinical data sources. Clinical events per 100 patient-years, total costs and
incremental cost effectiveness ratio (ICER) for both therapy regimens were evalu-
ated. The robustness and stability of the results were tested using sensitivity and
PSA analyses. RESULTS: Over a 10 years period patients treated with dabigatran in
comparison with those receiving dual antiplatelet therapy experienced fever isch-
emic strokes (1.8 vs. 3.49), extracranial bleedings (2.53 vs. 2.76) and hemorrhagic
strokes (0.41 vs. 0.44) per 100 patient-years. Total cost ofmedications accounted for
266,089 Roubles in dabigatran group and 249,870 Roubles in dual antiplatelet ther-
apy group, cost of complications treatment – 12,500 Roubles and 18,182 Roubles,
cost of follow-up after occurred complications and rehabilitation – 24987 Roubles
and 37620 Roubles per 100 patients respectively. In total, absolute cost-saving as-
sociated with dabigatran use was 20,948 Roubles per 100 patients. CONCLUSIONS:
Dabigatran use in stroke prevention in atrial fibrillation may be considered as
cost-saving alternative to aspirin plus clopidogrel combination in patients with
warfarin intolerance.
PCV60
COST-UTILITY OF POST-DISCHARGE EDUCATIONAL INTERVENTIONS IN
PATIENTS WITH ACUTE CORONARY SYNDROME OR CHRONIC HEART FAILURE
Couturier B1, Carrat F2, Cohen A1, Hejblum G3
1Assistance Publique - Hôpitaux de Paris, Paris, France, 2UPMC Univ Paris 06, Paris, France,
3Inserm, Paris, France
OBJECTIVES: The reported impact of post-discharge therapeutic educational inter-
ventions (TEIs) in patients with cardiovascular diseases is controversial and has
been poorly addressed in cost-utility studies.We developed amodeling framework
for studying the cost-utility of TEIs in this setting. METHODS: We modeled the
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